Amgen KRAS Inhibitor Less Effective In Colorectal Cancer Than Lung

New data for AMG 510 at ESMO show the drug is more active in lung than colorectal cancer, as was reported at ASCO, but Amgen's Greg Friberg notes that Phase I monotherapy and planned combination studies may shed more light on KRAS biology and efficacy in different tumor types.

Colon cancer. Cancer attacking cells. Colon disease concept. 3d illustration - Illustration
One of 12 colorectal cancer patients had a partial response to AMG 510. • Source: Shutterstock

Updated results for Amgen Inc.'s AMG 510, its small molecule targeting the G12C mutation of the KRAS oncogene, that were presented at the European Society for Medical Oncology (ESMO) meeting on 28 September in Barcelona, Spain, showed limited efficacy in colorectal cancer (CRC) patients, but the company is optimistic that its drug can perform better than approved CRC therapies, particularly in combination with other agents.

Only one out of 12 colorectal cancer patients (8%) treated with 960mg of AMG 510 daily – the highest dose...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

UCB Follows Fellow European Pharmas With Major US Investment

 
• By 

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.

More from R&D

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By 

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

 

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.